FDA Accepts Amneal and Adalvo ANDAs for Generic Tirzepatide Autoinjectors

Amneal Pharmaceuticals and Adalvo have reached a key regulatory milestone after the U.S. Food and Drug Administration (FDA) accepted for review two Abbreviated New Drug Applications (ANDAs) for generic tirzepatide autoinjectors. Submitted through the FDA’s NCE-1 process, the applications allow the agency to begin reviewing certain generic medicines before reference product exclusivity expires. Mounjaro and Zepbound are listed in the FDA’s Orange Book, where applicable exclusivity and patent information are maintained.

The applications cover all currently approved indications for the reference products, including treatment of adults with type 2 diabetes, chronic weight management in adults with obesity or overweight with weight-related conditions, and adults with moderate to severe obstructive sleep apnea (OSA). If approved, Amneal will lead U.S. commercialization of the products.

Clinical Mechanism and Therapeutic Relevance

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating both incretin pathways, it enhances glucose-dependent insulin secretion, reduces appetite, and slows gastric emptying, contributing to improved glycemic control and clinically meaningful weight loss.

Demand for tirzepatide has increased rapidly following its approvals across metabolic disease indications. According to IQVIA, U.S. tirzepatide sales across its approved indications, including type 2 diabetes, chronic weight management, and obstructive sleep apnea, increased from nearly $41 billion in 2025 to $72.8 billion in 2026.

Regulatory Pathway and Bioequivalence Requirements

The two ANDAs cover single-dose prefilled pen presentations equivalent to the reference autoinjector products. Because the applications are submitted through the ANDA pathway. they do not require new clinical efficacy trials. Instead, approval depends on demonstrating pharmaceutical equivalence and bioequivalence to the reference product, together with compliance with FDA quality and manufacturing standards.

Amneal and Adalvo are jointly developing the generic tirzepatide products, combining Adalvo’s expertise in complex injectable product development and global supply chain management with Amneal’s regulatory capabilities and established U.S. commercial infrastructure.

The FDA’s acceptance confirms that the applications are sufficiently complete for substantive scientific review. Final approval will depend on the agency’s assessment of product quality, manufacturing, bioequivalence, and compliance with all regulatory requirements.

Clinical and Regulatory Perspectives

Arni Baldursson, Chief Commercial Officer at Adalvo, said the FDA acceptance reflects the companies’ close collaboration on a technically challenging injectable program. He noted that tirzepatide represents the type of complex product that requires coordinated expertise across formulation, development, manufacturing, and regulatory functions.

Gregory Sgammato, Chief Corporate Development Officer at Amneal, said expanding access to affordable medicines remains a strategic priority as demand for GLP-1 therapies continues to grow. He added that approval would strengthen Amneal’s portfolio of complex injectable medicines, including GLP-1 therapies and drug-device combination products.

Regulatory Path Forward

The FDA will now conduct a full review of both ANDAs. If approved, the generic tirzepatide autoinjectors would provide additional treatment options for patients requiring long-term therapy for type 2 diabetes, obesity, and obstructive sleep apnea while expanding patient access and increasing competition in one of the fastest-growing metabolic therapy markets. The products would also expand Amneal’s presence in the complex injectable and metabolic disease segments through its collaboration with Adalvo.

Reference

Amneal Pharmaceuticals, Inc. – Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector